Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Data backs AZ’s Wilson disease drug, but with a question mark

Fujifilm acquires AI tech to improve fertility treatment

Sarepta shares yo-yo as FDA places hold on Duchenne trial

New countries stockpile antiviral TPOXX as monkeypox outbreak continues

Biogen and Happify partner on digital support for MS patients

PD-L1

OpdivoLarge

Cancer/ News/ UK & Europe

NICE rejects Opdivo in head and neck cancer – before it gains marketing approval

Andrew McConaghie BMS, immunotherapy, NICE, Oncology, Opdivo, PD-L1 0 Comment

England and Wales’ cost effectiveness watchdog NICE has rejected Opdivo for use against advanced head and neck cancer in

X

NICE rejects Opdivo in head and neck cancer – before it gains marketing approval

https://pharmaphorum.com/news/nice-rejects-opdivo-head-neck-cancer-gains-marketing-approval/

Merck-sign

Cancer/ News/ Pfizer

Avelumab filed, Pfizer and Merck prepare to join immunotherapy battle

Andrew McConaghie checkpoint inhibitors, immunotherapy, PD-L1 0 Comment

Checkpoint inhibitor drug set to be fourth competitor in PD-1/PD-L1 market

X

Avelumab filed, Pfizer and Merck prepare to join immunotherapy battle

https://pharmaphorum.com/news/avelumab-filed-pfizer-merck-prepare-join-immunotherapy-battle/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Novartis faces threat of early generic of MS drug Gilenya in US
Novartis bags FDA okay for BRAF-positive tumour combination
Pfizer is first big pharma to tap Truveta's real-world data platform
AbbVie files Qulipta for chronic migraine prevention
Moderna facility in UK confirmed, part of 10-year deal with gov't

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com